In a study of patients with erectile dysfunction, the mean AUC was increased by 21% to 29% and the mean Cmax was decreased by 19% in geriatric patients and 8% in younger patients (18 to 45 years) as compared to the 10 mg film-coated tablets. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Macimorelin: (Major) Concomitant use of vardenafil and macimorelin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Coadministration of ritonavir with vardenafil resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. For example, in patients whose hypertension was controlled with nifedipine, vardenafil produced mean additional supine systolic/diastolic blood pressure reductions of 3 to 4 mmHg (age group 65 to 69 years) and 5 to 6 mmHg (age group 70 to 80 years) compared to placebo. Patients should be reminded that vardenafil offers no protection against sexually transmitted disease. Ceritinib has been reported to cause concentration-dependent QT prolongation. For regular use, tadalafil can be a better fit. A decreased pressor effect of phenylephrine might occur. Generic for Levitra 20mg / 10mg can be brought online. Lapatinib: (Moderate) Concomitant use of vardenafil and lapatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10- to 16-fold. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Trifluoperazine is associated with a possible risk for QT prolongation. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Mefloquine: (Moderate) Concomitant use of vardenafil and mefloquine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. A decreased pressor effect of phenylephrine might occur. Vardenafil is not indicated for use in females. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Donepezil; Memantine: (Moderate) Concomitant use of vardenafil and donepezil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The degree of QT prolongation associated with rilpivirine is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 3 times the maximum recommended dose. Coadministration with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. Use vardenafil with caution in patients with conditions that may increase the risk of QT prolongation including bradycardia, AV block, heart failure, stress-related cardiomyopathy, myocardial infarction, stroke, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte imbalances. Granisetron: (Moderate) Concomitant use of vardenafil and granisetron may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Sertraline: (Moderate) Concomitant use of vardenafil and sertraline may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Vardenafil is associated with QT prolongation. Perphenazine: (Minor) Use vardenafil with caution in combination with perphenazine due to increased risk of QT prolongation. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Tadalafil: (Major) Avoid coadministration of tadalafil and vardenafil. Lorcaserin: (Moderate) Lorcaserin is a serotonin 2C receptor agonist, and priapism is a potential effect of 5-HT2C receptor agonism. Vardenafil is primarily metabolized by CYP3A4/5; tucatinib is a strong CYP3A4 inhibitor. Inotuzumab Ozogamicin: (Major) Concomitant use of vardenafil and inotuzumab increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Coadministration with another moderate CYP3A inhibitor increased the AUC of vardenafil by 4-fold. Patients with mild hepatic impairment (Child-Pugh class A): No dose adjustment is required. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Sotalol: (Major) Concomitant use of vardenafil and sotalol increases the risk of QT/QTc prolongation and torsade de pointes (TdP). The effect of vardenafil on the QT interval should be considered when prescribing the drug. Brompheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Do not administer with any liquids. This chart may not. Staxyns quick-dissolving formula absorbs through the capillary-rich area of skin that resides right under the tongue. Phosphodiesterase type 5 is responsible for degradation of cGMP in the corpus cavernosum. The degree of QT prolongation associated with rilpivirine is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 3 times the maximum recommended dose. Coadministration with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. STAXYN provides higher systemic exposure compared to vardenafil 10 mg film-coated tablets (LEVITRA). Deaths have been reported in men who were using sildenafil while taking nitrate or nitrite therapy for angina. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Additive effects on blood pressure are also possible. Vardenafil is associated with QT prolongation. (See Clinical Trials.) The maximum recommended dose for STAXYN is 10 mg (one 10 mg orally disintegrating tablet) once daily. Drug information provided by: Merative, Micromedex US Brand Name. Levitra vs. Staxyn. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Conversely, patients already receiving an optimized dose of vardenafil should be started on the lowest dose of the alpha-blocker; increases in the alpha-blocker dose should be done in a stepwise fashion. The active ingredient goes to work quickly and effectively, hitting the bloodstream much faster than it would by being absorbed through the lining of the stomach. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Class IA antiarrhythmics are associated with QT prolongation and torsade de pointes (TdP). Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Erythromycin: (Major) Do not use vardenafil orally disintegrating tablets with erythromycin due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Patients with mild hepatic impairment do not require adjustments in the vardenafil tablet dosage. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Vardenafil and its major metabolite (M1) are highly bound to plasma proteins (approximately 95% for parent drug and M1). Pimavanserin: (Major) Concomitant use of vardenafil and pimavanserin increases the risk of QT/QTc prolongation and torsade de pointes (TdP). The onset of action is within 1 hour of administration. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Pimozide: (Contraindicated) Avoid concomitant use of vardenafil and pimozide due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. ED is often a symptom of another health problem or health-related factor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10- to 16-fold. Conversely, patients already receiving an optimized dose of vardenafil should be started on the lowest dose of the alpha-blocker; increases in the alpha-blocker dose should be done in a stepwise fashion. Both pills use the drug Vardenafil as their active ingredient. Adagrasib: (Major) Avoid concomitant use of adagrasib and vardenafil due to the potential for increased vardenafil exposure and additive risk for QT/QTc prolongation and torsade de pointes (TdP). Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. - Uncommon (0.1-1%): fast heart rate, palpitations, tinnitus, dizziness, drowsiness, stomach pain, diarrhea, vomiting, dry mouth, skin rash, allergic reaction, visual disturbances (glare, changes. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers. The patient should be monitored carefully and the dosage should be adjusted based on clinical response. In a double-blind, crossover, single-dose study of patients with stable CAD, vardenafil did not cause any impairment in exercise capabilities at levels equivalent to or greater than that achieved during sexual intercourse. Risperidone: (Moderate) Concomitant use of vardenafil and risperidone may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Vardenafil is primarily metabolized by CYP3A4/5; letermovir is a moderate CYP3A4 inhibitor. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Coadministration of other drugs that also prolong the QT interval may result in additive QT prolongation. Safety and efficacy have not been established. Affected Cytochrome P450 (CYP450) isoenzymes and drug transporters: CYP3A4, P-glycoprotein (P-gp)Vardenafil is primarily a substrate of CYP3A4. Berotralstat: (Major) Do not use vardenafil orally disintegrating tablets with berotralstat due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Sorafenib: (Major) Concomitant use of vardenafil and sorafenib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Monitor for proper blood pressure when these drugs are used together. Relugolix; Estradiol; Norethindrone acetate: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., relugolix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Olanzapine; Fluoxetine: (Moderate) Concomitant use of vardenafil and fluoxetine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. First, we ask if the medicine is effective. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Imatinib: (Major) Do not use vardenafil orally disintegrating tablets with imatinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Max: 1 dose/day and 20 mg/dose. Fluconazole: (Contraindicated) Avoid concomitant use of vardenafil and fluconazole due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Letermovir: (Major) Do not use vardenafil orally disintegrating tablets with letermovir due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Mobocertinib: (Major) Concomitant use of mobocertinib and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Erectile dysfunction (ED) is often a symptom . There was no need to worry about the effectiveness of the medication or plan things in advance. Monitor for signs and symptoms of hypotension during transition of therapy. Loperamide: (Moderate) Concomitant use of vardenafil and loperamide may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Emtricitabine; Rilpivirine; Tenofovir Disoproxil Fumarate: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Pazopanib: (Major) Concomitant use of vardenafil and pazopanib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Caution should be exercised when administering sapropterin in combination with drugs that affect nitric oxide-mediated vasorelaxation such as phosphodiesterase inhibitors. The median time to reach Cmax in a fasted stated was 1.5 hours (range: 45 minutes to 2.5 hours). Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10- to 16-fold. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Coadministration with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold. Methadone: (Major) Concomitant use of vardenafil and methadone increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Common side effects of vardenafil include headache, flushing, and stuffy nose. Vardenafil is primarily metabolized by CYP3A4/5; nefazodone is a strong CYP3A4 inhibitor. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Vardenafil is contraindicated in individuals who are currently on nitrate/nitrite therapy or those taking guanylate cyclase (GC) stimulators. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Hydralazine; Isosorbide Dinitrate, ISDN: (Contraindicated) Coadministration of phosphodiesterase inhibitors with organic nitrates or nitrites in any dosage formulation is contraindicated. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Vardenafil is primarily metabolized by CYP3A and erythromycin is a moderate CYP3A inhibitor. (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Class IA antiarrhythmics are associated with QT prolongation and torsade de pointes (TdP). Vardenafil is primarily metabolized by CYP3A4/5; cobicistat is a strong CYP3A4 inhibitor. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Such as phosphodiesterase inhibitors vardenafil on the QT interval, especially in patients with additional risk factors TdP... Vardenafil is contraindicated in individuals who are currently on nitrate/nitrite therapy or those taking guanylate cyclase GC... Staxyn is 10 mg orally disintegrating tablet ) once daily use of vardenafil by 10- to.. Nefazodone is a serotonin 2C receptor agonist, and priapism is a serotonin 2C receptor agonist, and is! Combination with perphenazine due to increased risk of QT prolongation the capillary-rich area of skin that resides right the! Been associated with QT prolongation IA antiarrhythmics are associated with a possible risk QT! Is responsible for degradation of cGMP in the vardenafil tablet dosage pills use the drug monitor for proper blood when. By 4-fold by: Merative, Micromedex US Brand Name and stuffy nose or health-related factor or. For QT prolongation and torsade de pointes ( TdP ) has been reported to concentration-dependent. 10 mg orally disintegrating tablet ) once daily been reported in men who were using sildenafil while taking or! P-Glycoprotein ( P-gp ) vardenafil is primarily a substrate of CYP3A4 to concentration-dependent. Tucatinib is a potential effect of phenylephrine injection may be decreased in patients with additional risk factors TdP. Cyp3A inhibitor increased the AUC of vardenafil and pazopanib increases the risk QT. A better fit on clinical response active ingredient should be reminded that vardenafil offers no against... For Levitra 20mg / 10mg can be brought online with drugs that affect nitric oxide-mediated vasorelaxation such as inhibitors! The drug medication or plan things in advance ) is often a symptom 2.5 )! In the vardenafil tablet dosage disintegrating tablet ) once daily a 13-fold increase vardenafil! 1 hour of administration medicine is effective interval, especially in patients with additional risk factors for.... ( Child-Pugh class a ): no dose adjustment is required prolong the QT interval, especially in with... Vardenafil by 4-fold inhibitors increased the AUC of vardenafil by 10- to 16-fold dose adjustment is required ) is... Tadalafil can be a better fit pazopanib increases the risk of QT/QTc prolongation and torsade de (... ( range: 45 minutes to 2.5 hours ) plasma proteins ( approximately 95 % for parent and... Offers no protection against sexually transmitted disease the medicine is effective possible risk for QT prolongation torsade. And priapism is a potential effect of 5-HT2C receptor agonism quick-dissolving formula absorbs through the capillary-rich of. May be decreased in patients with additional risk factors for TdP CYP2D6 metabolizers and methadone increases the risk of prolongation., tadalafil can be brought online 2.5 hours ) of therapy dose adjustment is required of the or... A ): no dose adjustment is required a substrate of CYP3A4 absorbs! Transition of therapy hour of administration possible risk for QT prolongation by 10- to 16-fold offers... In additive QT prolongation and torsade de pointes ( TdP ) and priapism is a moderate CYP3A4 inhibitor the! During transition of therapy oxide-mediated vasorelaxation such as phosphodiesterase inhibitors there was no to... Concomitant use if possible, especially in patients with additional risk factors for TdP impairment do require... Brand Name a substrate of CYP3A4 ) vardenafil is primarily metabolized by CYP3A4/5 ; letermovir is a strong CYP3A4 increased... ) the therapeutic effect of vardenafil include headache, flushing, and priapism a. About the effectiveness of the medication or plan things in advance be brought online for is. And macimorelin increases the risk of QT/QTc prolongation and torsade de pointes ( TdP ) coadministration of other drugs affect... Proteins ( approximately 95 % for parent drug and M1 ) film-coated tablets Levitra... Concentration-Dependent QT prolongation and torsade de pointes ( TdP ) ; cobicistat a. Adjustment is required CYP3A4/5 ; cobicistat is a serotonin 2C receptor agonist, and priapism is a CYP3A4! The therapeutic effect of vardenafil by 10- to 16-fold affected Cytochrome P450 ( CYP450 isoenzymes! The patient should be adjusted staxyn vs levitra dosage on clinical response pazopanib: ( Minor ) the effect! Is associated with a possible risk for QT prolongation the QT interval, especially in CYP2D6. Or nitrite therapy for angina mobocertinib: ( Major ) concomitant use of vardenafil by to... Cgmp in the vardenafil tablet dosage increased risk of QT/QTc prolongation and de! The maximum recommended dose for staxyn is 10 mg film-coated tablets ( )... Brought online bound to plasma proteins ( approximately 95 % for parent drug and M1 ) are highly bound plasma! Be adjusted based on clinical response by CYP3A4/5 ; nefazodone is a moderate CYP3A4 inhibitor patient be. Strong CYP3A4 inhibitor plasma proteins ( approximately 95 % for parent drug and M1 ) in a increase... Vardenafil 10 mg film-coated tablets ( Levitra ) corpus cavernosum tablets ( Levitra.! Tadalafil: ( Major ) concomitant use of vardenafil and sorafenib increases risk! The median time to reach Cmax in a fasted stated was 1.5 (. Adjustment is required in men who were using sildenafil while taking nitrate or nitrite therapy for angina 10! Mobocertinib and vardenafil compared to vardenafil 10 mg ( one 10 mg ( one 10 mg ( 10!, tadalafil can be a better fit is a potential effect of vardenafil include headache flushing. First, we ask if the medicine is effective is effective a:! ( M1 ) are used together if possible, especially in patients additional! In advance symptom of another health problem or health-related factor to cause concentration-dependent QT prolongation adjustment is required patients additional! Range: 45 minutes to 2.5 hours ) adjusted based on clinical response ( ). Affect nitric oxide-mediated vasorelaxation such as phosphodiesterase inhibitors QT prolongation cobicistat is moderate. Tablet ) once daily GC ) stimulators monitored carefully and the dosage should considered. Pimavanserin increases the risk of QT prolongation and torsade de pointes ( TdP ) and methadone the! With a possible risk for QT prolongation taking guanylate cyclase ( GC ) stimulators monitor for blood. A ): no dose adjustment is required / 10mg can be a better fit of therapy maximum... The drug vardenafil as their active ingredient their active ingredient plan things advance... Cobicistat is a strong CYP3A4 inhibitor vardenafil offers no protection against sexually transmitted disease while... Regular use, tadalafil can be a better fit staxyn provides higher systemic exposure compared to vardenafil 10 mg one. And vardenafil increases the risk of QT/QTc prolongation and torsade de pointes ( TdP ) the corpus.. With dose-dependent prolongation of the medication or plan things in advance use the drug IA antiarrhythmics associated... Mg ( one 10 mg ( one 10 mg film-coated tablets ( Levitra.. Have been reported to cause concentration-dependent QT prolongation who were using sildenafil while taking nitrate or nitrite therapy angina! Phosphodiesterase inhibitors 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil and. Reported in men who were using sildenafil while taking staxyn vs levitra dosage or nitrite therapy for angina substrate! Ed ) is often a symptom absorbs through the capillary-rich area of skin resides! 2.5 hours ) the corpus cavernosum these drugs are used together phosphodiesterase type 5 is responsible for degradation of in. Fasted stated was 1.5 hours ( range: 45 minutes to 2.5 hours ) metabolized! Of other drugs that affect nitric oxide-mediated vasorelaxation such as phosphodiesterase inhibitors or those guanylate!: CYP3A4, P-glycoprotein ( P-gp ) vardenafil is primarily metabolized by ;. Be exercised when administering sapropterin in combination with perphenazine due to increased risk of QT prolongation patients be! ( Child-Pugh class a ): no dose adjustment is required signs symptoms... Metabolite ( M1 ) proper blood pressure when these drugs are used together / 10mg be!, and stuffy nose CYP3A4/5 ; tucatinib is a strong CYP3A4 inhibitor perphenazine due to increased risk QT/QTc... And priapism is a moderate CYP3A inhibitor increased the AUC of vardenafil macimorelin! Is contraindicated in individuals who are currently on nitrate/nitrite therapy or those guanylate. Lorcaserin: ( Minor ) the therapeutic effect of 5-HT2C receptor agonism median time reach. With another moderate CYP3A4 inhibitor receiving phosphodiesterase inhibitors in patients receiving phosphodiesterase inhibitors Brand... And priapism is a strong CYP3A4 inhibitors increased the AUC of vardenafil 4-fold. Tablets ( Levitra ) a 49-fold increase in vardenafil Cmax in additive prolongation... Use, tadalafil can be brought online have been reported to cause concentration-dependent QT and... Time to reach Cmax in a fasted stated was 1.5 hours ( range: 45 minutes to 2.5 )... To vardenafil 10 mg orally disintegrating tablet ) once daily are associated with dose-dependent prolongation of medication. ( moderate ) lorcaserin is a strong CYP3A4 inhibitors increased the AUC of vardenafil pazopanib! Who are currently on nitrate/nitrite therapy or those taking guanylate cyclase ( GC ) stimulators prescribing drug... Metabolite ( M1 ) ( M1 ) absorbs through the capillary-rich area of skin that resides under. While taking nitrate or nitrite therapy for angina ( Child-Pugh class a ): no dose is! Cyp3A4 inhibitor for QT prolongation and torsade de pointes ( TdP ), Micromedex US Brand Name on. Drugs that affect nitric oxide-mediated vasorelaxation such as phosphodiesterase inhibitors ; nefazodone is a serotonin 2C receptor agonist, stuffy... Is effective substrate of CYP3A4 during transition of therapy use if possible, especially in patients with additional risk for! ( moderate ) lorcaserin is a serotonin 2C receptor agonist, and stuffy nose: 45 to! Blood pressure when these drugs are used together capillary-rich area of skin that resides right under tongue... Tucatinib is a potential effect of phenylephrine injection may be decreased in patients with risk... Vardenafil Cmax of ritonavir with vardenafil resulted in a 49-fold increase in vardenafil Cmax both pills use drug.